Kinled Holding

Kinled Holding is a privately held investment firm with a rich heritage spanning over a century, rooted in the Anglo-Austrian Aisher family's entrepreneurial and industrial endeavors since 1924. The firm operates as a diversified investment company, focusing on direct and fund investments in innovative businesses across the Life Science, Financial, and Digital Technology sectors. Kinled emphasizes a long-term, adaptive approach to investing, prioritizing wealth creation in terms of opportunity, purpose, and progress for its partners, team members, co-investors, and shareholders.

The firm's investment strategy is deeply rooted in financing deep technological breakthroughs. In life sciences, Kinled focuses on biomedical technology, medical devices, robotics, precision medicine, drug discovery, neuromodulation, and digital healthcare services. Within digital technologies, investments target SaaS-enabled networks and marketplaces, with a strong emphasis on digital health. In the fintech sector, Kinled supports companies that leverage technology to disrupt traditional financial institutions, particularly in embedded payment platforms, insurance, real estate, lending, and banking. The firm holds a portfolio of 175 investments, both directly and through specialized funds.

Kinled is actively involved in fostering innovation, particularly by transforming academic ventures into commercial entities. This is achieved through the establishment of venture accelerators in Austria and Switzerland, such as Cebina (Central European Biotech Incubator & Accelerator) and Mountain Labs, which focuses on artificial intelligence, quantum computing, and brain-computer interfaces. The firm also manages EU-regulated funds like Danube BioVentures, which targets pharmaceutical drug development and biomedical innovations, especially in dementia research. Kinled frequently co-invests with leading venture capital firms and family offices, and is a founding partner or limited partner in ten independent funds with combined assets under management of approximately €525 million.

The Aisher family's legacy of innovation dates back to 1924, with four generations having built and scaled successful companies across various sectors, including building materials, plastics, retail, real estate, geospatial data software, biotech, precision medicine, fintech, banking, robotics, and quantum computing. Kinled's corporate team is dedicated to identifying and nurturing groundbreaking opportunities, having funded early-stage businesses originating from numerous universities across Austria, Switzerland, the United States, and other European countries. The firm maintains offices and laboratories within innovation hubs like the Swiss Federal Institute of Technology and the BioCampus of the University of Vienna.